Effect of cationic carriers on the pharmacokinetics and tumor localization of nucleic acids after intravenous administration

被引:91
作者
de Wolf, Holger K. [1 ]
Snel, Cor J. [1 ]
Verbaan, Ferry J. [1 ]
Schiffelers, Raymond M. [1 ]
Hennink, Wim E. [1 ]
Storm, Gert [1 ]
机构
[1] Univ Utrecht, Dept Pharmaceut, Utrecht Inst Pharmaceut Sci, NL-3508 TB Utrecht, Netherlands
关键词
siRNA complexes; pDNA complexes; polyplexes; tumor localization; circulation kinetics; intravenous administration;
D O I
10.1016/j.ijpharm.2006.10.029
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Nucleic acid based therapeutics are currently being studied for their application in cancer therapy. In this study, the effect of different cationic delivery systems on the circulation kinetics, tumor localization, and tissue distribution of short interfering RNA (siRNA) and plasmid DNA (pDNA) was examined, after intravenous administration in mice bearing a s.c. Neuro 2A tumor. Nanosized particles were formed upon complexation of siRNA with the cationic liposome formulation DOTAP/DOPE and the targeted, cationic polymer RGD-PEG-PEI. Both the circulation kinetics and the overall tumor localization of the siRNA complexes were similar to non-complexed siRNA. Importantly, the different carriers changed the intratumoral distribution of siRNA within the tumor. pDNA was effectively condensed with linear polyethylenimine (PEI), PEGylated linear PEI (PEG-PEI) or poly(2-dimethylamino ethylamino)phosphazene. Only PEG-PEI was able to improve the pDNA circulation kinetics. All pDNA complexes yielded similar pDNA tumor localization (1% of the injected dose, 60 min after administration). We conclude that the level of nucleic acid tumor localization is independent on the type of formulation used in this study. Therefore, the value of carrier systems for the intravenous delivery of nucleic acids cannot be solely attributed. to benefits relevant during the transport towards the tumor. Rather, the benefits are arising from carrier-induced changes in the intratumoral fate of the nucleic acids. (c) 2006 Elsevier B.V. All rights reserved.
引用
收藏
页码:167 / 175
页数:9
相关论文
共 51 条
[1]   Progress towards in vivo use of siRNAs [J].
Behlke, MA .
MOLECULAR THERAPY, 2006, 13 (04) :644-670
[2]   Biodistribution of phosphodiester and phosphorothioate siRNA [J].
Braasch, DA ;
Paroo, Z ;
Constantinescu, A ;
Ren, G ;
Öz, OK ;
Mason, RP ;
Corey, DR .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (05) :1139-1143
[3]   The effect of formulation parameters on the size of poly-((2-dimethylamino)ethyl methacrylate)-plasmid complexes [J].
Cherng, JY ;
Talsma, H ;
Verrijk, R ;
Crommelin, DJA ;
Hennink, WE .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 1999, 47 (03) :215-224
[4]   Factors affecting blood clearance and in vivo distribution of polyelectrolyte complexes for gene delivery [J].
Dash, PR ;
Read, ML ;
Barrett, LB ;
Wolfert, M ;
Seymour, LW .
GENE THERAPY, 1999, 6 (04) :643-650
[5]   Lipoplex-mediated delivery of nucleic acids: factors affecting in vivo transfection [J].
Dass, CR .
JOURNAL OF MOLECULAR MEDICINE-JMM, 2004, 82 (09) :579-591
[6]   In vivo tumor transfection mediated by polyplexes based on biodegradable poly(DMAEA)-phosphazene [J].
de Wolf, HK ;
Luten, J ;
Snel, CJ ;
Oussoren, C ;
Hennink, WE ;
Storm, G .
JOURNAL OF CONTROLLED RELEASE, 2005, 109 (1-3) :275-287
[7]  
DEONG JY, 2005, FUTURE ONCOL, V1, P361
[8]   Current strategies in cancer gene therapy [J].
El-Aneed, A .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2004, 498 (1-3) :1-8
[9]  
Fenske DB, 2001, CURR OPIN MOL THER, V3, P153
[10]   Delivery systems for antisense oligonucleotides [J].
Garcia-Chaumont, C ;
Seksek, O ;
Grzybowska, J ;
Borowski, E ;
Bolard, J .
PHARMACOLOGY & THERAPEUTICS, 2000, 87 (2-3) :255-277